Toripalimab-related ureteritis:a case report
10.12173/j.issn.1005-0698.202407049
- VernacularTitle:特瑞普利单抗相关输尿管炎1例
- Author:
Jianbo FENG
1
;
Yanyan ZHAO
;
Huixian ZHANG
;
Zhen LIU
Author Information
1. 济宁医学院附属医院肿瘤科(山东济宁 272029)
- Publication Type:Journal Article
- Keywords:
Toripalimab;
Breast cancer;
Ureteritis;
Adverse drug reactions
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(1):105-110
- CountryChina
- Language:Chinese
-
Abstract:
A 48-year-old woman was treated with toripalimab for triple negative breast cancer.She developed symptoms of pollakiuria and urinary urgency after 1st cycle of toripalimab,and was hospitalized for severe abdominal pain after 2nd circle of treatment,after symptomatic treatment,the condition improved.However,after the 3rd,4th,and 5th cycles of medication,the symptoms recurred.The symptoms did not reappear after discontinuing toripalimab.Therefore,ureteritis associated with immune checkpoint inhibitors(ICI)was considered based on case characteristics,urine routine,urine culture,ultrasound and CT findings.According to Naranjo's Assessment Scale,the association between toripalimab and ureteritis was considered"definite".The possibility of ureteritis associated with ICI should be considered if symptoms of urinary tract irritation occur during the use of toripalimab,and urine analysis,urine culture,and imaging examination should be conducted to detect such adverse reactions earlier.
